News
Public · Published
LIVN: Double-digit Q3 growth lifted 2026 guidance as core franchises expanded and OSA investment advanced
LivaNova reported third-quarter revenue of $393 million, up 10%, led by growth in its Cardiopulmonary and Epilepsy businesses. It raised its 2026 revenue and adjusted earnings-per-share guidance, kept free cash flow guidance unchanged, and continued investment in oxygenator capacity and obstructive sleep apnea development.
Published:
Updated:
What happened
LivaNova reported third-quarter revenue of $393 million, up 10%, led by growth in its Cardiopulmonary and Epilepsy businesses. It raised its 2026 revenue and adjusted earnings-per-share guidance, kept free cash flow guidance unchanged, and continued investment in oxygenator capacity and obstructive sleep apnea development.
Confirmed
Global impact / market context
Higher revenue and raised forecasts point to stronger expected sales and adjusted earnings, while unchanged free cash flow guidance suggests the company has not raised its cash-generation outlook. Oxygenator expansion and sleep apnea development require investment, which may affect costs and future growth.
Analyst inference
The reported growth came from Cardiopulmonary and Epilepsy, while investment in oxygenator capacity and obstructive sleep apnea development continues. For investors, the key tension is whether expansion and product development can support revenue and earnings without weakening the cash outlook.
Analyst inference
What to watch
- Check future reports for whether Cardiopulmonary and Epilepsy growth continues, since those businesses were identified as the main contributors to the 10% third-quarter revenue increase. Analyst inference
- Look for updates to 2026 revenue and adjusted earnings-per-share guidance, which would show whether the raised outlook is maintained or changed as the year progresses. Analyst inference
- Watch for progress on oxygenator capacity expansion and obstructive sleep apnea development, as spending on these efforts may influence costs and future sales opportunities. Analyst inference
Evidence
- Original source link unavailable